Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

NCT04858334 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04858334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04858334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
June 22, 2021
Completion date
October 31, 2027
Enrollment
152 (estimated)
Sites
456

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic acinar cell carcinoma, pancreatic adenosquamous carcinoma, pancreatic squamous cell carcinoma, resectable pancreatic acinar cell carcinoma, resectable pancreatic adenocarcinoma, resectable pancreatic adenosquamous carcinoma, resectable pancreatic carcinoma